NanoViricides, Inc. Files SEC Form 10-SB
PrintE-mailDisable live quotesRSSDigg itDel.icio.usRelated Blog Posts & ArticlesLast Update: 8:01 AM ET Nov 15, 2006
WEST HAVEN, Conn., Nov 15, 2006 (BUSINESS WIRE) -- NanoViricides, Inc. (NNVC, currently trading on Pink Sheets), -is pleased to report that it has filed Form 10-SB with the Securities and Exchange Commission to become a fully reporting company. The filing can be viewed at the SEC's website: sec.gov
The Company now awaits comments, if any, from the SEC. Once declared effective by the SEC, the Company will be eligible for listing on the NASD Over the Counter Bulletin Board (OTCBB).
The Company encourages its shareholders to read through the filing which details NanoViricides' accomplishments to date and its strategy for future growth.
The Company also reported that our scientists are continuing to put in extremely long workdays as they prepare for the next stage of the scheduled in-vivo and in-vitro studies.
About NanoViricides - www.nanoviricides.com
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. A NanoViricide(TM) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile. NanoViricide drugs are designed to block and dismantle the virus particles before they can infect a cell, thereby controlling viremia. This is a completely novel approach that is proving to be superior to existing approaches. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.
SOURCE: NanoViricides, Inc.
NanoViricides, Inc. Leo Ehrlich, 917-853-6440 leo@nanoviricides.com Copyright Business Wire 2006
|
